Genomics of MPNST

Neurofibromatosis Type 1 Tumor Early Detection (NF1-TED) Study

The Neurofibromatosis Type 1 Tumor Early Detection (NF1-TED) trial will study whether a blood test can detect malignant peripheral nerve sheath tumors (MPNSTs) in participants with NF1 earlier than the current standard of care.


If interested, email NF1-TED@childrens.harvard.edu


Eligibility Criteria

  • 18 years or older

  • Diagnosis of Neurofibromatosis Type 1 (NF1)

  • History of plexiform neurofibroma (PN)

Participant Responsibilities

At the beginning of the study, and every six months during the five-year follow-up period, participants will be asked to provide a blood sample and complete a brief online questionnaire.

If a participant develops an MPNST, the study team will request additional clinical data and a sample from the MPNST collected during regular clinical care from your doctor.

Why Participate?

There will be the opportunity to earn up to $425.00 over the five-year follow-up period. You will also be participating in a study that could help improve the lives of people with NF1 in the future.



NFRI Events and Updates